NCT01652131

Brief Summary

There is no objective evidence of how long intravenous solutions remain inside venous blood vessels after they have been administered, therefore there is no definite guideline of how to administer them in the preoperative setting. Besides, obese patients represent a particular group of subjects as they theoretically with-hold a constant inflammatory response and that would modify the way solutions behave intravenously, that is how long they remain inside. Having said this, we wish to describe the way colloid solutions behave in this group of patients by taking serial blood samples in 12 obese patients after a colloid infusion, to calculate plasma dilution curves based on hemoglobin dilution and therefore infer the time it remains intravascularly. All this in the hope this information will help, in the near future, to establish a more objective way to use these solutions and avoid possible complications due to over-administration.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
12

participants targeted

Target at below P25 for not_applicable obesity

Timeline
Completed

Started May 2012

Shorter than P25 for not_applicable obesity

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2012

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

July 25, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 27, 2012

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

November 20, 2012

Status Verified

November 1, 2012

Enrollment Period

7 months

First QC Date

July 25, 2012

Last Update Submit

November 18, 2012

Conditions

Keywords

general anesthesiavolume kinetics

Outcome Measures

Primary Outcomes (1)

  • description of colloid volume kinetics in obese patients after the infusion of Tetrastarch (130/0.4)

    different kinetic parameters will be used to asses the behavior of the colloid solution

    90 minutes after beginning of the infusion

Study Arms (1)

Tetrastarch (130/0.4)

OTHER

In obese patients candidates to laparoscopic gastrojejunal bypass an infusion of Tetrastarch (130/0.4)) of 15mL/kg (of corrected weight) will be initiated after protocoled induction of general anesthesia. Blood samples will be taken at time 0 (after induction of anesthesia and before initiating infusion) and then every 5 minutes for half an hour and then every 15 minutes up to 90 minutes. Blood samples will be processed in the Institution's laboratory. Urine will be measured at the end of the intervention. With these data kinetic parameters will be estimated for each patient.

Other: Tetrastarch (130/0.4)

Interventions

Also known as: Voluven 6%
Tetrastarch (130/0.4)

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • clinical diagnosis of obesity (IMC \>35kg/m2) that will be treated with gastrojejunal laparoscopic bypass

You may not qualify if:

  • Renal failure KDOQI \>3
  • Cardiac failure NYHA III-IV
  • Sepsis
  • Allergy to tetrastarch
  • Allergy to any of the anesthetic medication that is to be used in the protocol previously established
  • Patients in which vasoactive drugs are used
  • Patients in which the blood samples are completed.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institute of Medical Sciences, Salvador Zubiran

Mexico City, Mexico City, 14000, Mexico

RECRUITING

MeSH Terms

Conditions

ObesityObesity, Morbid

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Miguel F Herrera Hernandez, MD MSc PhD

    National Institute of Medical Sciences, Salvador Zubiran

    STUDY DIRECTOR
  • Maria V Hernandez Martinez, M.D.

    National Institute of Medical Sciences, Salvador Zubiran

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Maria V Hernandez Martinez, M.D.

CONTACT

Guillermo Dominguez Cherit, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D.

Study Record Dates

First Submitted

July 25, 2012

First Posted

July 27, 2012

Study Start

May 1, 2012

Primary Completion

December 1, 2012

Study Completion

December 1, 2012

Last Updated

November 20, 2012

Record last verified: 2012-11

Locations